New strategies in motor parkinsonismAngelo Antonini
Parkinson Institute, Istituti Clinici di Perfezionamento Milano, Italy
Parkinsonism Relat Disord 13:S446-9. 2007
..Interestingly, this procedure produces a satisfactory therapeutic response that is paralleled by a reduction in dyskinesia severity...
Pisa syndrome without neuroleptic exposure in a patient with Parkinson's disease: case reportMattia Gambarin
Dipartimento di Scienze Neurologiche e della Visione, Sezione di Neurologia Riabilitativa, , Verona, Italy
Mov Disord 21:270-3. 2006
..Because dopamine transporter imaging revealed bilateral and symmetrical reduction of striatal uptake, we suggest that PS is not primarily related to side differences in dopaminergic denervation or drug exposure...
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's diseaseAngelo Antonini
Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
Lancet Neurol 6:826-9. 2007
..Because of the clinical consequences of the adverse reactions, we suggest that affinity for 5-HT(2B) receptors is routinely tested in future drugs, in the laboratory or in animals, before they are given to patients...
Duodenal levodopa infusion improves quality of life in advanced Parkinson's diseaseA Antonini
Parkinson Institute, Istituti Clinici di Perfezionamento, Milano, Italia
Neurodegener Dis 5:244-6. 2008
..The use of apomorphine infusion is limited by compliance while deep brain stimulation is feasible only for a small number of patients mostly because of age constraints...
Validation of the Italian version of the Movement Disorder Society-Unified Parkinson's Disease Rating ScaleAngelo Antonini
Department for Parkinson s Disease, IRCCS San Camillo, via Alberoni 70, Venice, Italy
Neurol Sci 34:683-7. 2013
..The Italian version of the MDS-UPDRS reaches the criterion to be designated as an Official Translation and is now available for use. This protocol will serve as outline for further validation of this in multiple languages...
The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of lifeAngelo Antonini
Department for Parkinson s Disease, IRCCS San Camillo, via Alberoni 70, Venice, Italy
J Neurol 259:2621-31. 2012
..These results have consequences for drug studies targeting non-motor features...
Role of pramipexole in the management of Parkinson's diseaseAngelo Antonini
Department for Parkinson Disease, IRCCS San Camillo, Venice, Italy
CNS Drugs 24:829-41. 2010
..Pramipexole is generally well tolerated; however, compared with levodopa treatment, pramipexole is associated with a higher rate of some dopaminergic adverse effects...
Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disordersAngelo Antonini
Department for Parkinson s Disease, IRCCS San Camillo, Venice, Italy
Funct Neurol 25:21-5. 2010
..Furthermore, the rationale for the treatment of PD with the rotigotine transdermal patch is discussed, focusing in particular on the related sleep disorders...
Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's diseaseAngelo Antonini
Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
Parkinsonism Relat Disord 15:S97-100. 2009
..This has consequences in resource allocation and in estimating cost-benefit ratios for these complex therapies in advanced PD...
Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's diseaseAngelo Antonini
IRRCS, San Camillo, Viale Alberoni 70, Venice, Italy
CNS Drugs 24:119-29. 2010
..We propose a treatment algorithm that takes into account all currently available levodopa-based treatment strategies for motor complications in patients with PD...
Continuous dopaminergic stimulation--from theory to clinical practiceAngelo Antonini
Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
Parkinsonism Relat Disord 13:S24-8. 2007
..Duodenal levodopa produced significant clinical benefit without behavioural changes and allowed patients to discontinue all other PD medications. Duodenal levodopa should be considered in PD patients with advanced disease...
Wearing-off scales in Parkinson's disease: critique and recommendationsAngelo Antonini
Department for Parkinson s Disease and Movement Disorders, IRCCS San Camillo, Venice, Italy
Mov Disord 26:2169-75. 2011
..Among the other severity assessment tools, the Unified Parkinson Disease Rating Scale version 3 and the version revised from the Movement Disorders Society were classified as Suggested, whereas the Treatment Response Scale was Listed...
Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient managementAngelo Antonini
Parkinson Institute Milan, Istituti Clinici di Perfezionamento, Via Bignami 1, Milan, Italy
Expert Rev Neurother 9:859-67. 2009
..We also address the issue of selection criteria and propose clinical characteristics of candidates to help the clinician choose the most suitable option for their patients...
Single photon-emission computed tomography imaging in early Parkinson's diseaseAngelo Antonini
Parkinson Institute, Istituti Clinici di Perfezionamento, 20126 Milan, Italy
Expert Rev Neurother 8:1853-64. 2008
..We will also discuss the role of imaging of monoaminergic nondopamine systems to assess nonmotor features...
Pharmacokinetic evaluation of pramipexoleAngelo Antonini
Department for Parkinson Disease, IRCCS San Camillo, Venice, Italy
Expert Opin Drug Metab Toxicol 7:1307-14. 2011
..Additional advantages could include the opportunity to provide more continuous drug delivery in a fashion that could help minimize dyskinesia risk, if the drug is used early in the disease course...
Dopamine agonist-based strategies in the treatment of Parkinson's diseaseAngelo Antonini
Istituti Clinici di Perfezionamento, Parkinson Institute, Via Bignami 1, Milan, Italy
Neurol Sci 29:S371-4. 2008
..In this review we will examine factors contributing to treatment decision-making and discuss how a proper balance between motor and non-motor features should be aimed for in approaching PD therapy...
Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and preventionAngelo Antonini
Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
Drug Saf 32:475-88. 2009
..Given the social and potentially medical-legal consequences of these behaviours, we encourage treating physicians to discuss risks with patients before treatment is initiated...
Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcomeAngelo Antonini
Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
Mov Disord 22:1145-9. 2007
..05). Two patients withdrew for adverse events. Our results demonstrate that a satisfactory therapeutic window can be achieved and maintained for several months in advanced PD patients...
Continuous dopaminergic delivery in Parkinson's diseaseAngelo Antonini
Department for Parkinson s Disease, IRCCS San Camillo and University of Padova, Venice, Italy
J Neurol 257:S305-8. 2010
..Conversely, replacing whole oral therapy with levodopa infusion bypasses gastric emptying and avoids peaks and troughs in plasma by releasing levodopa in the duodenum/jejunum...
Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in ItalyAngelo Antonini
Parkinson Institute, Milan, Italy
Mov Disord 23:2202-9. 2008
..123)I-FP-CIT SPECT is likely to be regarded as economically advantageous to differentiate ET from PD, increasing time on potentially beneficial therapy at a lower overall cost to the healthcare system...
Genetic, clinical, and imaging characterization of one patient with late-onset, slowly progressive, pantothenate kinase-associated neurodegenerationAngelo Antonini
Parkinson Institute and Neuroradiology, Istituti Clinici di Perfezionamento, Milan, Italy
Mov Disord 21:417-8. 2006
..These findings expand the genetic and imaging spectrum of this rare disorder...
The rationale for improved integration between home care and neurology hospital services in patients with advanced Parkinson's diseaseAngelo Antonini
Parkinson Institute Milan, Istituti Clinici di Perfezionamento, Via Bignami 1, Milan, Italy
Neurol Sci 29:S392-6. 2008
..This would reduce unnecessary internal medicine hospitalisations and further highlight the role of neurologists as a key health care figure...
Clinical and cerebral activity changes induced by subthalamic nucleus stimulation in advanced Parkinson's disease: a prospective case-control studyRoberto Cilia
Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
Clin Neurol Neurosurg 111:140-6. 2009
..Functional imaging evidenced pathological overactivity in motor cortical areas in advanced PD that can be normalized by effective therapies...
Regression of cardiac valvulopathy related to ergot-derived dopamine agonistsRenzo Zanettini
Cardiac Rehabilitation Unit, Istituti Clinici diPerfezionamento, Via Bignami 1, Milan, Italy
Cardiovasc Ther 29:404-10. 2011
..We followed-up our original cohort of patients to ascertain whether valvulopathy regressed after discontinuation of treatment and/or its incidence increased over time...
Cognitive status of patients with Parkinson's disease and pathological gamblingChiara Siri
Parkinson Institute, Istituti Clinici di Perfezionamento, 20126, Milan, Italy
J Neurol 257:247-52. 2010
..In conclusion the occurrence of PG in our cohort of patients with PD was associated with preserved executive functions...
A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulationAngelo Antonini
Parkinson Institute, Istituti Clinici di Perfezionamento, Via Bignami, 1, 20126, Milan, Italy
J Neurol 258:579-85. 2011
..Decrement of medications was greater with STN-DBS. There was a significant worsening of NPI after STN-DBS, primarily because four subjects developed apathy...
Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disordersAnnamaria Vallelunga
Molecular Neurobiology Laboratory, IRCCS San Camillo, via Alberoni 70, 35126 Venice Lido, Italy
Parkinsonism Relat Disord 18:397-9. 2012
..We assessed whether allelic variants of dopamine D2 receptors (DRD2), catechol-O-methyltransferase (COMT) and dopamine transporter (DAT) were associated with the development of ICDs in PD...
Impulsivity and compulsivity in drug-naïve patients with Parkinson's diseaseAngelo Antonini
Department of Neurology, Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
Mov Disord 26:464-8. 2011
..However, impulsivity and compulsive symptoms have never been explored in PD patients before initiation of DRT. We previously reported a 20% of impulse control disorders (ICD) in an Italian cohort...
LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sampleStefano Goldwurm
Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
Parkinsonism Relat Disord 12:410-9. 2006
..Clinical features in carriers were those of typical, idiopathic Parkinson's disease. However, behavioural abnormalities were frequent (87%), suggesting a more widespread limbic involvement in G2019S carriers...
Striatal dopamine transporter abnormalities in patients with essential tremorIoannis U Isaias
Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
Nucl Med Commun 29:349-53. 2008
..Discriminant analysis was used to categorize healthy subjects and patients with Parkinson's disease or essential tremor...
[123I]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onsetIoannis U Isaias
Parkinson Institute, Istituti Clinici di Perfezionamento, Milan 20126, Italy
Neuroreport 18:1499-502. 2007
..We conclude that widespread degeneration of the nigrostriatal dopaminergic pathway might be necessary for the development of parkinsonian tremor-at-rest...
The PRIAMO study: background, methods and recruitmentAngelo Antonini
Parkinson Institute, Milan, Italy
Neurol Sci 29:61-5. 2008
..PRIAMO has analysed a total of 1307 patients (out of 1325 initially enrolled). We expect that PRIAMO will substantially help to quantify the burden of NMS in patients with parkinsonism...
Functional abnormalities underlying pathological gambling in Parkinson diseaseRoberto Cilia
Parkinson Institute, Istituti Clinici di Perfezionamento, Via Bignami 1, 20126 Milano, Italy
Arch Neurol 65:1604-11. 2008
..Pathological gambling (PG) may develop in patients with Parkinson disease (PD) during dopamine replacement therapy, but the underlying neural correlates are still unclear...
Brain networks underlining verbal fluency decline during STN-DBS in Parkinson's disease: an ECD-SPECT studyRoberto Cilia
Parkinson Institute, Istituti Clinici di Perfezionamento, Via Bignami 1, 20126, Milan, Italy
Parkinsonism Relat Disord 13:290-4. 2007
..Worsening fluency was associated with perfusion decrements in left dorsolateral prefrontal cortex, anterior cingulate cortex and ventral caudate nucleus (p<.001)...
Psychiatric symptoms in Parkinson's disease assessed with the SCL-90R self-reported questionnaireChiara Siri
Parkinson Institute, Istituti Clinici di Perfezionamento, Via Bignami, 1, 20123, Milan, Italy
Neurol Sci 31:35-40. 2010
..Psychopathological features are frequent in PD and their occurrence is underlined by disease-related factors...
Successful subthalamic stimulation in genetic Parkinson's disease caused by duplication of the α-synuclein geneAngelo Antonini
Parkinson Department, IRCCS San Camillo, Venice, Italy
J Neurol 259:165-7. 2012
..STN-DBS is safe and effective in patients with SNCA duplication showing a clinical pattern similar to idiopathic PD. Our case suggests that clinical phenotype rather genotype is the main predictor for DBS outcome...
alpha-Synuclein multiplication analysis in Italian familial Parkinson diseaseFrancesca Sironi
Parkinson Institute, Istituti Clinici di Perfezionamento, Via Bignami 1, 20126 Milan, Italy
Parkinsonism Relat Disord 16:228-31. 2010
..Although SNCA duplication is an unusual cause of familial PD testing for it is worthwhile. The clinical presentation of duplicated cases may be more aggressive than usual...
Parkin analysis in early onset Parkinson's diseaseFrancesca Sironi
Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
Parkinsonism Relat Disord 14:326-33. 2008
..735delT (p.C212/X224) and c.815C>G (p.C238W). Genotype-phenotype correlation revealed that parkin carriers had features similar to those of non-carrier early onset Parkinson disease patients...
A voxel-based PET study of dopamine transporters in Parkinson's disease: relevance of age at onsetAndrea Panzacchi
Department of Nuclear Medicine, Scientific Institute San Raffaele, Milan, Italy
Neurobiol Dis 31:102-9. 2008
..This work demonstrates that severity of nigrostriatal damage in early disease phase of sporadic PD is not dependent on age at onset. Genetically determined PD is associated with more severe and widespread dopaminergic impairment...
Imaging essential tremorIoannis U Isaias
Department of Human Physiology, University of Milano, Milano, Italy
Mov Disord 25:679-86. 2010
..In conclusion, PD and ET do not share a common pattern of dopaminergic loss over time. However, mild impairment of dopamine transporter in the caudate nucleus may contribute to tremor onset in ET...
Cognitive bizarreness in the dream and waking mentation of nonpsychotic patients with Parkinson's diseaseArmando D'Agostino
Department of Medicine, Surgery and Dentistry, Universita degli Studi di Milano, Milan, Italy
J Neuropsychiatry Clin Neurosci 22:395-400. 2010
....
The effect of repeated administrations of granulocyte colony stimulating factor for blood stem cells mobilization in patients with progressive supranuclear palsy, corticobasal degeneration and multiple system atrophyGianni Pezzoli
Parkinson Institute, Istituti Clinici di Perfezionamento, Via Bignami 1, 20126 Milan, Italy
Clin Neurol Neurosurg 112:65-7. 2010
..GCSF can be safely administered to patients with atypical parkinsonism and potentially meaningful clinical changes may be observed in some patients. These results are encouraging and warrant further studies...
Surgical, medical, and hardware adverse events in a series of 141 patients undergoing subthalamic deep brain stimulation for Parkinson diseaseFrancesco Vergani
Neurosurgery Department, University of Milano Bicocca, Milan, Italy
World Neurosurg 73:338-44. 2010
..Adverse events, due to surgical and hardware-related complications, must be clearly addressed to properly balance the cost-effectiveness of the therapy. In addition, limited data exists about medical adverse events after surgery...
MR imaging of the superior profile of the midbrain: differential diagnosis between progressive supranuclear palsy and Parkinson diseaseAndrea Righini
Department of Neuroradiology Istituti Clinici di Perfezionamento, Milan, Italy
AJNR Am J Neuroradiol 25:927-32. 2004
..CONCLUSION: An abnormal superior profile of the midbrain facilitates the distinction of PSP from PD and may support the clinical differential diagnosis of parkinsonism...
Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of lifeAngelo Antonini
Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
Mov Disord 21:1119-22. 2006
..However, the improvement in specific PDQ-39 subscores (mobility, activities of daily living, and stigma) suggests that depression affects patient self-perception of motor function and further emphasizes the need for its treatment...
Valvular heart disease and the use of dopamine agonists for Parkinson's diseaseRenzo Zanettini
Cardiac Rehabilitation Unit, Istituti Clinici di Perfezionamento, Milan, Italy
N Engl J Med 356:39-46. 2007
..Ergot-derived dopamine receptor agonists, often used in the treatment of Parkinson's disease, have been associated with an increased risk of valvular heart disease...
Dopamine Transporter SPECT Imaging in Corticobasal SyndromeRoberto Cilia
Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
PLoS ONE 6:e18301. 2011
..In addition, we assessed prevalence and features of individuals with CBS and in vivo evidence of preserved nigral neuronal density...
Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutationIoannis U Isaias
Centro Parkinson, Istituti Clinici di Perfezionamento, Milan, Italy
Mov Disord 21:1144-7. 2006
..We conclude that in these patients carrying the LRRK2 Gly2019Ser mutation, the neurodegenerative process results in a pattern of nigrostriatal dopaminergic dysfunction similar to that observed in IPD...
The relationship between impulsivity and impulse control disorders in Parkinson's diseaseIoannis U Isaias
Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
Mov Disord 23:411-5. 2008
..Impulse control disorders are also common in the control population. Individual susceptibility factors, such as high impulsivity and depression, underline abnormal behaviors in PD patients treated with stable dopaminergic therapy...
Extradural motor cortex stimulation in Parkinson's diseaseRoberto Cilia
Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
Mov Disord 22:111-4. 2007
..In our PD cohort, EMCS induced no objective benefit, although some subjective improvement was reported mostly on axial symptoms...
Diagnostic and screening power of neuropsychological testing in detecting mild cognitive impairment in Parkinson's diseaseRoberta Biundo
Department for Parkinson s Disease, Fondazione Ospedale San Camillo I R C C S, via Alberoni 70, Venice, Italy
J Neural Transm 120:627-33. 2013
..These results have consequences for cognitive diagnosis and potentially in establishing the rate of PD cognitive decline...
Pulsatile or continuous dopaminomimetic strategies in Parkinson's diseaseDaniela Calandrella
Department for Parkinson s Disease, Clinic San Pio X, Milan, Italy
Parkinsonism Relat Disord 18:S120-2. 2012
..Infusion therapies may reverse motor complications in complicated patients with significant benefit on quality of life...
Brain volume changes in Parkinson's disease and their relationship with cognitive and behavioural abnormalitiesRoberta Biundo
Department for Parkinson s Disease, IRCCS San Camillo, via Alberoni 70, 35126 Venice Lido, Italy
J Neurol Sci 310:64-9. 2011
..Our results suggest that PD is characterized by an overall loss of gray matter in pre-frontal regions. However, the contribution of these changes to the development of ICDs is marginal...
Clinical experience of tolcapone in advanced Parkinson's diseaseMargherita Canesi
Parkinson Institute, Istituti Clinici di Perfezionamento, Via Bignami 1, 20126, Milan, Italy
Neurol Sci 29:S380-2. 2008
..Our findings indicate that tolcapone widens the levodopa therapeutic window, even in patients who have not benefited from entacapone. We suggest that tolcapone is indicated before patients are referred for more invasive procedures...
Single-photon emission computed tomography in diagnosis and differential diagnosis of Parkinson's diseaseIoannis U Isaias
Department of Physiology, University of Milan, Milan, Italy
Neurodegener Dis 7:319-29. 2010
....
Cognitive and MRI correlates of orthostatic hypotension in Parkinson's diseaseManuela Pilleri
Department of Parkinson Disease and Movement Disorders, IRCCS San Camillo, Lido di Venezia, Venice, Italy
J Neurol 260:253-9. 2013
..Our study confirms that there is an association between OH and selective cognitive deficits in PD, but rebuts the hypothesis that this is underlined by the development of cerebrovascular disease...
Thin section MR study of the basal ganglia in the differential diagnosis between striatonigral degeneration and Parkinson diseaseAndrea Righini
Radiology and Neuroradiology Service, Hospital V Buzzi, Milan, Italy
J Comput Assist Tomogr 26:266-71. 2002
..We evaluated the specificity and sensitivity of an acquisition protocol using thin section MRI to differentiate MSA-P from Parkinson disease (PD)...
Pathological gambling in Parkinson's disease: disease related or drug related?Daniela Calandrella
Parkinson s Disease Department, Clinic San Pio X, Milan, Italy
Expert Rev Neurother 11:809-14. 2011
..This evidence is consistent with a significant contribution of disease-related factors...
A reassessment of risks and benefits of dopamine agonists in Parkinson's diseaseAngelo Antonini
Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
Lancet Neurol 8:929-37. 2009
..The risks of these potentially serious adverse events must therefore be taken into account and treatment decisions should be based on considerations of risks versus benefits for individual patients...
Bilateral subthalamic deep brain stimulation in a patient with Parkinson's disease who had previously undergone thalamotomy and autologous adrenal grafting in the caudate nucleus: case reportFrancesco Vergani
Department of Neurosciences and Biomedical Technology, University of Milano-Bicocca, Milan, Italy
Neurosurgery 59:E1140; discussion E1140. 2006
....
COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor featuresAngelo Antonini
Parkinson Institute, Istituti Clinici di Perfezionamento Milan, Italy
Neuropsychiatr Dis Treat 4:1-9. 2008
..Moreover, we suggest that tolcapone should be considered before surgical or infusional strategies are applied...
PET and SPECT functional imaging in Parkinson's diseaseAngelo Antonini
Dipartimento di Neuroscienze, Centro per la malattia di Parkinson, Istituti Clinici di Perfezionamento, Via Bignami 1, 20125 Milan, Italy
Sleep Med 5:201-6. 2004
..Conversely, the use of neuroimaging techniques can significantly shorten the diagnostic process and prove a useful means to the neurologist in those cases presenting with uncertain clinical diagnosis...
Is there room for new non-dopaminergic treatments in Parkinson's disease?Manuela Pilleri
Department for Parkinson s Disease, IRCCS San Camillo, via Alberoni 70, Venice, Italy
J Neural Transm 120:349-52. 2013
....
Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: implications for patientsAngelo Antonini
Department for Parkinson s Disease, IRCSS San Camillo, Venice, Italy
Neuropsychiatr Dis Treat 7:297-302. 2011
..Additional advantages may be represented by the opportunity to provide continuous drug delivery in a fashion that could potentially help minimize dyskinesia risk if the drug is used early in the disease course...
[Cost analysis in Italy of various strategies for the treatment of Parkinson disease in the advanced phase]Anna D'Ausilio
Chiesi Farmaceutici, Parma
Recenti Prog Med 94:484-93. 2003
....
Pramipexole-treated Parkinson's disease during pregnancyMarco Mucchiut
Clinica Neurologica, Policlinico Universitario, pzza Rodolone 2, 33013 Gemona del Friuli, Udine, Italy
Mov Disord 19:1114-5. 2004
..The child, born by caesarean delivery, is healthy, whereas motor disability of the mother progressively increased to the point that levodopa therapy was necessary...
Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonismAndrew Feigin
Center for Neuroscience, North Shore University Hospital, Manhasset, New York and New York University School of Medicine, New York, New York, USA
Mov Disord 17:1265-70. 2002
..Because of significant individual subject overlap between groups, however, the clinical utility of this method in the differential diagnosis of Parkinsonism remains uncertain...
Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control studyGiovanni Defazio
Department of Neurology and Psychiatry, University of Bari, Piazza Giulio Cesare 11, I 70124 Bari, Italy
Arch Neurol 65:1191-4. 2008
..To determine whether pain is more frequent among people with Parkinson disease (PD) than among age-matched controls...
Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's diseaseAlessio Di Fonzo
Department of Clinical Genetics, Erasmus MC Rotterdam, Rotterdam, The Netherlands
Eur J Hum Genet 14:322-31. 2006
..These data have implications both for understanding the molecular mechanisms of PD, and for directing the genetic screening in clinical practice...
Whole gene deletion and splicing mutations expand the PINK1 genotypic spectrumRoberta Marongiu
IRCCS CSS Mendel Institute, Rome, Italy
Hum Mutat 28:98. 2007
..15445_15467del23) which produces several aberrant mRNAs. This report expands the genotypic spectrum of PINK1 mutations, with relevant implications for molecular analysis of this gene...
Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutationMaria Teresa Giordana
Department of Neuroscience, University of Torino, Torino, Italy
Mov Disord 22:275-8. 2007
..These findings support the concept that the neurodegeneration associated with LRRK2 mutations might be clinically and pathologically indistinguishable from typical PD...
Anatomical identification of active contacts in subthalamic deep brain stimulationFrancesco Vergani
Department of Neurosciences and Medical Biotechnologies, University of Milano Bicocca, 20052 Monza, Italy
Surg Neurol 67:140-6; discussion 146-7. 2007
..Identifying the location of active contacts for StnDBS can yield interesting insights on the mechanisms of action of DBS and the different role played by the anatomical structures of the subthalamic region...
Role of DAT-SPECT in the diagnostic work up of parkinsonismChristoph Scherfler
Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
Mov Disord 22:1229-38. 2007
..This review addresses the value of DAT-SPECT in early differential diagnosis, and its potential as a screening tool for subjects at risk of developing PD as well as issues around the assessment of disease progression...
PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrumRoberta Marongiu
IRCCS CSS Mendel Institute, Rome, Italy
Hum Mutat 29:565. 2008
..Hence, their significance should be kept distinct from that of homozygous/compound heterozygous mutations, that cause parkinsonism inherited in a mendelian fashion...
Novel parkin mutations detected in patients with early-onset Parkinson's diseaseAida M Bertoli-Avella
Genetic Epidemiologic Unit, Department of Clinical Genetics and Department of Epidemiology and Biostatistics, Erasmus MC Rotterdam, The Netherlands
Mov Disord 20:424-31. 2005
..This study confirms the frequent involvement of parkin and the importance of genetic testing in the diagnostic work-up of EOP...
Biological effects of the PINK1 c.1366C>T mutation: implications in Parkinson disease pathogenesisAnne Grünewald
Department of Neurology, University of Lubeck, Ratzeburger Allee 160, 23538 Lubeck, Germany
Neurogenetics 8:103-9. 2007
..1366C>T mutation...
Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized studyPaolo Barone
Department of Neurological Sciences, University of Naples Federico II, Via Pansini 5, 80131, Napoli, Italy
J Neurol 253:601-7. 2006
..We conclude that dopamine agonists may be an alternative to antidepressants in Parkinson's disease...